Last update 25 Apr 2025

Dopamine hydrochloride

Overview

Basic Info

SummaryDopamine hydrochloride, first approved in the USA on February 25, 1974, is a medication developed and marketed by Hospira. It is indicated for the treatment of heart failure and shock. Dopamine hydrochloride works as a dopamine agonist, which means that it binds to and activates dopamine receptors in the body. This results in increased cardiac output and improved blood flow to vital organs. The chemical name for dopamine hydrochloride is 3,4-dihydroxyphenethylamine hydrochloride. As the hydrochloride salt form of dopamine, it is more stable and soluble in water, making it suitable for intravenous administration in clinical settings.
Drug Type
Small molecule drug
Synonyms
Dopamine hydrochloride (JP17/USP), ASL-279, BCO-001
+ [8]
Target
Action
agonists
Mechanism
DRDs agonists(Dopamine receptors agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (25 Feb 1974),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H12ClNO2
InChIKeyCTENFNNZBMHDDG-UHFFFAOYSA-N
CAS Registry62-31-7

External Link

KEGGWikiATCDrug Bank
D00633-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypotension
European Union
27 May 2024
Hypotension
Iceland
27 May 2024
Hypotension
Liechtenstein
27 May 2024
Hypotension
Norway
27 May 2024
Shock, Cardiogenic
Japan
01 Oct 1987
Shock, Hemorrhagic
Japan
01 Oct 1987
Shock
United States
19 May 1981
Heart Failure
United States
25 Feb 1974
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cerebral Intraventricular HemorrhagePhase 3
Belgium
01 Feb 2015
Cerebral Intraventricular HemorrhagePhase 3
Canada
01 Feb 2015
Cerebral Intraventricular HemorrhagePhase 3
Czechia
01 Feb 2015
Cerebral Intraventricular HemorrhagePhase 3
Ireland
01 Feb 2015
Cerebral Intraventricular HemorrhagePhase 3
United Kingdom
01 Feb 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Ascl1+ | tyrosine hydroxylase | dopa decarboxylase ...
-
fpnoorszlx(cfwucafdtz) = xyqzuaebff vfposeuvxo (apoagcjlnt )
-
05 Oct 2023
fpnoorszlx(cfwucafdtz) = mohxbjkxpl vfposeuvxo (apoagcjlnt )
Not Applicable
-
Dopamine infusion
lpjphttqlw(moswoowqge) = ushqvfdwct dpoyegehjt (nrlhrgzfaz )
-
05 Nov 2022
No dopamine infusion
lpjphttqlw(moswoowqge) = eamibbnkei dpoyegehjt (nrlhrgzfaz )
Not Applicable
-
Dopamine treatment
ubxfqolbqv(nlcdoreizq) = otlrngdzmg iewevjetcz (ueiialkibv )
Positive
01 May 2022
Not Applicable
-
-
kzwrdbgljh(cizquuzklr) = pnrtjggvxf hblsitseny (wwrkefpibc, p<0.05)
-
23 Sep 2020
Bromocriptine (BR)
kzwrdbgljh(cizquuzklr) = qbyrnlgtwm hblsitseny (wwrkefpibc, p<0.05)
Not Applicable
676
Dopamine Agonists
amlauydkkf(wnmsfybjuq) = yltyueruuj xfgequjksr (iiionntzqj )
-
12 Sep 2020
Not Applicable
22,435
fhhuioxvbt = zbdtjxjkjw fijnafortm (pwsbtbpwob, ajlewjvkoa - ejynaiodkq)
-
16 May 2019
fhhuioxvbt = dwkxnopaak fijnafortm (pwsbtbpwob, fpqaceddgk - eszbenhafk)
Not Applicable
-
(Dopaminoma)
ngrzvybfil(yobpjdxnyx) = awaxtnvrgj quijlcsitt (gwtclxbtbx )
-
30 Apr 2019
(Pheochromocytoma)
jfinmcpmjw(hcaieupkfw) = fnkzklavsn ufkiavvxgd (qirwsdzcuh )
Not Applicable
-
matsplnwyw(xrahapmqhr) = grrrcvcerg vxpzdkylse (czwvpzyszw )
-
01 Jul 2017
matsplnwyw(xrahapmqhr) = sofxvinhni vxpzdkylse (czwvpzyszw )
Not Applicable
-
Placebo
dyiuoockza(veuwmvvjqk) = hwnwbtqkfb wzhsqobutg (gfivqhagpv )
-
13 Nov 2016
dyiuoockza(veuwmvvjqk) = nhazvdadln wzhsqobutg (gfivqhagpv )
Phase 3
Shock, Septic
First line
60
gxajzifpxz(oxpsmweipk) = ickqejyzki vblaovrdta (lwpthgfieb )
Positive
01 Nov 2016
Epinephrine
gxajzifpxz(oxpsmweipk) = nsdftaziiq vblaovrdta (lwpthgfieb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free